Navigation Links
Oncothyreon reports full year and fourth quarter 2007 financial results
Date:3/10/2008

.............. - 462 - 462

--------- ---------- ---------- ----------

Net loss.................. $ (5,152) $ (27,113) $ (20,340) $ (36,394)

--------- ---------- ---------- ----------

--------- ---------- ---------- ----------

Basic and diluted loss

per share................ $ (0.26) $ (1.58) $ (1.04) $ (2.38)

--------- ---------- ---------- ----------

--------- ---------- ---------- ----------

Weighted average number of

common shares outstanding

(in thousands)........... 19,486 17,133 19,486 15,317

--------- ---------- ---------- ----------

--------- ---------- ---------- ----------

Oncothyreon Inc.(1)

Consolidated Balance Sheets Data

(in thousands of U.S. dollars, except share data)

(unaudited)

December 31, December 31,

2007 2006

Cash, cash equivalents and short term

investments.................................. $ 24,186 $ 28,395

Total assets.................................. $ 36,218 $ 33,456

Total long-term liabilities................... $ 12,526 $ 2,328

Shareholders' equity.......................... $ 12,019 $ 27,435

Common shares outstanding..................... 19,485,889 19,485,889

(1) On December 10, 2007, Oncothyreon became the successor corporation to

Biomira Inc. by way of a plan of arrangement effected pursuant to

Canadian law. These financial statements reflect the h
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Oncothyreon announces March 10th webcast of fourth quarter and full year financial results conference call
2. Oncothyreons PX-478 is effective in preclinical model of human lung cancer
3. Oncothyreon launches new corporate website
4. Oncothyreon to present at BIO CEO & Investor Conference
5. Oncothyreon highlights corporate and clinical objectives for 2008
6. Biomira announces plan to change name to Oncothyreon
7. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
8. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
9. ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
10. Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
11. ProMetic reports continued positive data in PBI-1402 phase II trial in chemotherapy-induced anemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... -- Research and Markets has announced the ... report to their offering. ... the genetic material or genomes of an organism. It ... discovery and development of diagnostic and therapeutic solutions for ... is supported by three major product segments: Instruments, Consumables, ...
(Date:7/31/2014)... San Francisco, Calif. (PRWEB) July 31, 2014 ... provides newly diagnosed patients with an overview of the ... the management of drug side effects, as well as ... , “We’re grateful to Dr. Sandy Srinivas for organizing ... 25-year survivor of kidney cancer. “Sandy and her colleagues ...
(Date:7/31/2014)... , July 31, 2014   BioLife Solutions ... developer, manufacturer and marketer of proprietary clinical grade ... and precision thermal shipping products for cells ... quarter 2014 financial results will be released on Thursday, ... a conference call and live webcast at 4:30 p.m. ...
(Date:7/30/2014)... Calif. , July 30, 2014 ... a biopharmaceutical company leading the discovery and development of ... report financial results and highlights for the quarter ended ... the U.S. financial markets close. Regulus ... August 6, 2014, at 5:00 pm Eastern Daylight Time ...
Breaking Biology Technology:Global Genomics Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Life Technologies, Qiagen and Illumina 2BioLife Solutions to Report Financial Results for Second Quarter 2014 and Provide Business Update on August 7, 2014 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 3
... the promotions of Linda Arterburn, PhD, Francisco Leon, MD, ... "We are pleased,to announce the promotions of several of ... a fine group of talented people working here to ... with celiac,disease, asthma, eye disorders, and other areas to ...
... Business Update to Investors, WILMINGTON, Del., Oct. ... Vice President & General Manager John Ranieri,said the ... programs to,market are on track and making significant ... conversion of cellulosic feedstocks,economically into biofuels., "Biobutanol ...
... OF PHASE II DATA FOR LEAD DRUG CANDIDATE ... Oct. 2 Transave, Inc., a,biopharmaceutical company focused ... of serious lung diseases,today announced that it has ... and Compass Horizon Funding Company LLC, an affiliate ...
Cached Biology Technology:Alba Therapeutics Corporation Announces Promotions 2Alba Therapeutics Corporation Announces Promotions 3Alba Therapeutics Corporation Announces Promotions 4DuPont Meeting Significant 2008 Milestones in Progressing Advanced Biofuels 2DuPont Meeting Significant 2008 Milestones in Progressing Advanced Biofuels 3Transave, Inc. Secures $12.5 Million in New Financing 2Transave, Inc. Secures $12.5 Million in New Financing 3Transave, Inc. Secures $12.5 Million in New Financing 4Transave, Inc. Secures $12.5 Million in New Financing 5
(Date:7/31/2014)... the brain processes speech, potentially increasing the difficulty ... The University of Texas at Dallas. , In ... and Hearing , researchers demonstrated for the first ... recognition of speech sounds. , Noise-induced hearing loss ... an estimated 15 percent of Americans between the ...
(Date:7/31/2014)... identify and treat those with fibromuscular dysplasia (FMD). FMD ... arteries in the body, which can restrict blood flow to ... report appearing in August 2014 issue of The ... may not be limited to the arteries as currently believed. ... and joints, as well as evidence that inflammation may be ...
(Date:7/31/2014)... the Rim Fire was in full fury, raging swiftly ... entered the backcountry of Yosemite National Park in California,s ... park, the battle began to turn, enacting a case ... combine to fuel large, severe fires. , "When the ... where fire had been used as a management tool, ...
Breaking Biology News(10 mins):UT Dallas study reveals effect of loud noises on brain 2Scientists discover biochemical mechanisms contributing to fibromuscular dysplasia 2The Rim Fire 1 year later: A natural experiment in fire ecology and management 2The Rim Fire 1 year later: A natural experiment in fire ecology and management 3The Rim Fire 1 year later: A natural experiment in fire ecology and management 4The Rim Fire 1 year later: A natural experiment in fire ecology and management 5
... will present the 2013 William Dameshek Prize to Andrew S. ... research on the cellular and molecular causes of blood clots. ... MD, a renowned hematologist, past president of ASH, and the ... an individual who has made a recent, outstanding contribution to ...
... known as important sources of energy for all organisms. ... certain types of sugars, known as polysaccharides, may also control ... produce hard structures such as shells and exoskeletons of mollusks, ... of the National Academy of Sciences , Anthony Giuffre, a ...
... is killing you, you may be right, but what you ... even before you were born. In a new report appearing ... Journal , Harvard researchers find that epigenetic disruptions, which ... common at birth. Possibly, these aberrations result from stressors in ...
Cached Biology News:The American Society of Hematology honors Andrew S. Weyrich, Ph.D., with 2013 William Dameshek Prize 2Geoscientists unearth mineral-making secrets potentially useful for new technologies 2Geoscientists unearth mineral-making secrets potentially useful for new technologies 3Fetal stress disrupts the way genes are transmitted 2
Rabbit polyclonal to MAL ( Abpromise for all tested applications). entrezGeneID: 4118 SwissProtID: P21145...
Anti-ADAM-12 (Meltrin Alpha); amino terminal region; rabbit host...
Rabbit polyclonal to FLIP ( Abpromise for all tested applications). entrezGeneID: 8837 SwissProtID: O15519...
Mouse monoclonal [3G8] to MDMA ( Abpromise for all tested applications)....
Biology Products: